CNNMoney.com – A major shareholder of Amylin Pharmaceuticals Inc. ( AMLN) is backing a slate of dissident directors nominated by Carl Icahn and another hedge-fund manager, Eastbourne Capital Management.

P. Schoenfeld and Associates, which owned 2.1 million Amylin shares as of the end of the first quarter, told Dow Jones Newswires Thursday it supports all five of Icahn’s and Eastbourne’s nominees because it sees that as the only opportunity for the company to make significant strides.

"We would like to see the largest minority possible elected to the Amylin board," said P. Schoenfeld founder Peter Schoenfeld.

Read Complete Article

Tags: 1-million, amln, amylin pharmaceuticals inc, capital-management, carl-icahn, dow jones newswires, dow-jones, first quarter, hedge-fund-manager, schoenfeld, shareholder, slate, strides

Bloomberg – Hedge fund Eastbourne Capital Management LLC nominated five directors to the board of Amylin Pharmaceuticals Inc. and is supporting a slate put forward by investor Carl Icahn, after it “lost confidence” in leadership of the maker of the Byetta diabetes drug.

Eastbourne, which owns 12.5 percent of San Diego-based Amylin, said in a letter to management yesterday that the company’s board needs to be “significantly strengthened” after the stock fell almost 80 percent since Oct. 5, 2007. In November, Eastbourne said it was talking with Amylin about options including “a possible acquisition by a third party.”

Read Complete Article

Tags: acquisition, amylin pharmaceuticals inc, byetta, capital-management-llc, carl-icahn, confidence, diabetes, diabetes drug, investor, leadership, oct 5, s board, san diego, slate, stock, third-party